HARMONY proudly presents three abstracts that clearly demonstrate the added value of big data in predicting patient outcomes in hematologic malignancy research. We invite ASH2023 conference participants to listen and interact with our experts, find below a peek preview of their research. In addition to abstract presentations, HARMONY Partner ELN (European Leukemia Network) organises its annual ASH breakfast meeting.
Alberto Hernández, University Hospital of Salamanca, will present about Machine Learning Provides Individualized Prediction of Outcomes after First Complete Remission in Adult AML Patients – Results from the HARMONY Big Data Platform
Sjoerd Hermans, Erasmus MC, will present about Outcome of Intensively Treated Elderly AML Patients Reported to the Harmony Alliance Compares Well to Outcome of Control Patients of the Prospective Randomized HOVON 103 Study in Elderly AML.
Luca Guarnera, Policlinico Universitario di Roma Tor Vergata, will present about Long-Term Outcome of 1296 Patients with Newly Diagnosed with APL: A HARMONY Alliance Study
Find more information about the abstract and details about presentation dates, times, rooms and related links below:
Oral presentation: Machine Learning Provides Individualized Prediction of Outcomes after First Complete Remission in Adult AML Patients – Results from the HARMONY Big Data Platform
A model providing individualized outcome estimations in adult AML patients with intensive treatment approaches was developed and validated. Predictions for relapse-free survival, cumulative incidence of relapse and overall survival were more accurate than those in the ELN2022 risk stratification. The model is accessible online via an interactive web calculator, and with further validation and refinement, it could be used in the future for clinical decision-making.
Poster presentation: Outcome of Intensively Treated Elderly AML Patients Reported to the Harmony Alliance Compares Well to Outcome of Control Patients of the Prospective Randomized HOVON 103 Study in Elderly AML
The evaluation of novel drugs in hemato-oncology is hampered by the relatively large sample sizes needed in RCTs. Supplementing trial data with external control data could overcome this obstacle. Our comparative study revealed that HARMONY Alliance data matched RCT data well for overall survival. Matched HARMONY Alliance data could therefore supplement prospectively collected control data in studies evaluating intensive therapy in elderly AML.
Oral presentation: Long-Term Outcome of 1296 Patients with Newly Diagnosed with APL: A HARMONY Alliance Study
Acute promyelocytic leukemia (APL) is now curable in 75-90% of patients using targeted agents. RCTs revealed similar patient outcomes for chemotherapy and non-chemotherapy treatment regimens. However, the reliability of these outcomes was limited by the small patient cohorts used. Our long-term analysis using the larger HARMONY APL registry patient cohort revealed a significant survival advantage for the non-chemotherapy regimen with reduced early death rates and prolonged overall survival independent of Sanz risk score.
During this breakfast session organized by the European Leukemia Network, delegates will have the opportunity to get up to speed with the latest HARMONY Alliance research developments. HARMONY and ELN Work Package Leaders will present research summary reports. HARMONY Alliance KOLs, among which Rudiger Hehlmann, Andreas Hochhaus, Paolo Ghia, Jesus Maria Hernandez Rivas, Lars Bullinger, will give an update on recent developments in HARMONY and HARMONY PLUS. Furthermore our plans for the HARMONY Alliance Research Foundation will be shared.
Apart from our abstract presenters many of our HARMONY Alliance Partners are traveling to San Diego to participate in ASH2023. Would like to meet up on site? We are very interested to hear about your research and the impact you seek to make on hematology patients’ lives. And you can explore whether our approach of using big data and AI in blood cancer research, without compromising quality, safety or patient privacy, could open up new avenues for you. Please do not hesitate to send an email to: Ellen de Waal, Lead HARMONY Alliance Communications at communications@harmony-alliance.eu.
7 years of intense HARMONY Alliance collaboration.
#Bigdataforbloodcancer: Revolutionizing the use of big data in Hematologic Malignancies research.
When the HARMONY Alliance started in 2017, the hematology community was embarking on a journey towards embracing data sharing and recognizing the transformative power of big data. HARMONY set a crucial milestone when this endeavor was only starting. By laying the foundation for future collaborations, advancements, and discoveries that would incorporate state-of-the-art technologies in the field of hematology, HARMONY is making its contribution to improve the understanding and treatment of blood disorders. Now, just almost seven years later with 128 partners from 28 countries, we have transformed both the sharing and use of data. We have developed the Big Data Platform with a data lake that has identified over 160,000 patient records. All data is protected using a unique anonymization and security process. In more than 30 research projects, groundbreaking research is being carried out with the help of advanced customized data analytic services, including AI modelling.
Receive the latest news. Click here to subscribe!
Public-private partnership for Big Data in Hematology
HARMONY and HARMONY PLUS are funded through the Innovative Medicines Initiative (IMI), Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. Funding is received from the IMI 2 Joint Undertaking and is listed under grant agreement for HARMONY No. 116026 and grant agreement for HARMONY PLUS No. 945406. This Joint Undertaking receives support from the European Union’s Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).
HARMONY Coordination Office
Institute of Biomedical Research of
Salamanca (IBSAL)
Salamanca, Spain
HARMONY Communications
European Hematology Association (EHA)
The Hague, The Netherlands
